← Back to Search

Antibiotic

ARV-1801(ACG-701) Active Group for Cystic Fibrosis (REPRIEVE Trial)

Phase 2

Waitlist Available

Research Sponsored by Aceragen

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Participants must have a moderate or Severe Patient Global Impression of Severity

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 7

Awards & highlights

REPRIEVE Trial Summary

This trial will assess a new oral drug's effectiveness and safety in treating Cystic Fibrosis-related lung flare-ups, compared to a placebo.

Eligible Conditions

Cystic Fibrosis

REPRIEVE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

You must feel that your symptoms are moderate or severe.

REPRIEVE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 7

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 7

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 7 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Desirability in outcome ranking (DOOR)

REPRIEVE Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: ARV-1801(ACG-701) Active GroupActive Control1 Intervention

ARV-1801(ACG-701) tablets by mouth twice a day for 14 days

Group II: Placebo GroupPlacebo Group1 Intervention

Placebo tablets by mouth twice a day for 14 days

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

AceragenLead Sponsor

1 Previous Clinical Trials

125 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA accepted ARV-1801/ACG-701 Active Group for medicinal use?

"The safety of ARV-1801/ACG-701 Active Group was rated a 2, as there is some data to back up its safety but not yet enough evidence supporting its efficacy."

Answered by AI

What number of participants has joined this research effort?

"Affirmative. Clinicaltrials.gov reveals that this medical trial, initiated on February 10th 2023, is actively searching for participants. 80 test subjects are needed from 2 healthcare centres."

Answered by AI

Are researchers presently recruiting participants for this research project?

"Affirmative, the information on clinicaltrials.gov suggests that this medical experiment is actively seeking participants. The trial was uploaded to the website on February 10th 2023 and revised for accuracy lastly on February 14th of the same year. 80 individuals are needed across 2 sites for successful completion of this investigation."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations

2023. "Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05641298.